ClinicalTrials.gg
Active, not recruitingNCT00745355Updated Sep 25, 2026

Quality of Life in Patients With Bladder Cancer

An observational study in Bladder Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

Updated Sep 25, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
550
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 47 studies in Urinary Bladder Neoplasms by Memorial Sloan Kettering Cancer Center — 4 open to participants now, 13 under way, 1 of them phase 3. Urinary Bladder Neoplasms · Memorial Sloan Kettering Cancer Center.

Started
2008
with 2 others
Observational
7 of 47
none open now
Primary completion
2027-08
later than 7 of 12 live
Registered
17th of 47
by date

Among the 47 studies in Urinary Bladder Neoplasms by Memorial Sloan Kettering Cancer Center, this one is one of 3 that started in 2008, is one of 7 observational ones, reaches primary completion later than 7 of the 12 other live ones, and was the 17th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

4 of the 47 studies in Urinary Bladder Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Urinary Bladder Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the quality of life of people living with bladder cancer. We are interested in learning about how the treatments for bladder cancer affect people. We plan to use the findings from this study to help doctors provide better care and information to patients with bladder cancer.

03

Conditions studied

  • Bladder Cancer

Keywords

  • Quality of Life
  • Questionnaires
  • 08-076
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All eligible MSKCC patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients (male and female) who are diagnosed with bladder cancer
  • Patients must be scheduled for radical cystectomy and urinary diversion are and/or being evaluated for chemotherapy prior to a planned cystectomy.
  • Participants must be able to speak English.
  • Participants must be able to provide .
  • Participants must be 18 years of age or older to enroll.
  • Participant may be eligible for and may receive neoadjuvant or adjuvant chemotherapy.
  • Participant may have had intravesicle chemotherapy or immunotherapy (BCG, Interferon).

Exclusion criteria

Exclusion Criteria:

  • Subjects may be excluded from the study based on the following criteria:
  • Follow-up care not obtained at MSKCC.
  • disease at diagnosis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
550 participants (estimated)

Groups and cohorts

  • 1

    new patients with bladder cancer and/or are scheduled for radical cystectomy and urinary diversion

    Behavioral: Quality Of Life questionnaires

Interventions

  • BehavioralQuality Of Life questionnaires

    All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.

06

What researchers measure

Primary outcomes

  1. Prospectively characterize the impact of radical cystectomy and different urinary diversions on quality of life of bladder cancer patients.

    Time frame: conclusion of study

Secondary outcomes

  1. Compare various standard and idiographic measures of QOL, to determine their relative contributions in accounting for variance in key outcome criteria and prediction of patient QOL at subsequent assessment points.

    Time frame: conclusion of study

  2. Examine how patients react to more in-depth probing of the interview associated with idiographic assessment.

    Time frame: conclusion of study

  3. Develop a predictive model of QOL after radical cystectomy & urinary diversion using the data from idiographic and standard QOL measures. This model can ultimately be used in office based practice to guide treatment planning with each patient.

    Time frame: conclusion of study

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Aug 2008, a primary completion of Aug 2027 and a completion of Aug 2027. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Aug 2026 → Aug 2027 and completion Aug 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2008
First posted
Sep 3, 2008
Start
Aug 2008
Primary completionEst.
Aug 2027was Aug 2026
CompletionEst.
Aug 2027was Aug 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Aug 2027
Sep 25, 2026
Study completion
Aug 2026→Aug 2027
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Primary completion Aug 2026→Aug 2027
    Study completion Aug 2026→Aug 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00745355
Collaborators
Albert Einstein College of Medicine, Northwell Health, Lenox Hill Hospital, DeltaQuest Foundation, Inc., Lahey Hospital & Medical Center
Responsible party
Sponsor
First posted
Sep 3, 2008
Start date
Aug 2008
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Bernard Bochner, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion